Company profile
Bot Verification
Amlo Biosciences Limited is a UK company with status active founded in 2017.
Financial period: 1 Dec 2023 to 30 Nov 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
CS01 | Transaction MzQ0MDI4NTE5N2FkaXF6a2N4
Published 21 Oct 2024 10:44
Last confirmation statement made up date
Company registered at Companies House
AMLo Biosciences develops a test for early stage cancer patients designed to determine the risk levels of the disease spreading.
AMLo Biosciences has identified two proteins (AMBLor) in the epidermis overlying the primary tumour that are lost in high-risk melanoma that can be assessed using standard automated immunohistochemistry, fitting seamlessly into existing pathology procedures. AMBLor has been validated in over 400 melanoma Stage I biopsies classified under the new 8th edition of AJCC staging, with known clinical outcomes. Use of this test can accurately predict melanomas that are genuinely low-risk and those that are high-risk with greater sensitivity and specificity than any other prognostic melanoma test. AMBLor also gives better prognostic information than SLNB in tumours with Breslow depth <2mm. AMLo Biosciences intends to produce a diagnostic kit to assess AMBLor in tumour tissue biopsies suitable for use in pathology labs worldwide with real potential to reduce costs to healthcare services, provide reassurance and improve patient outcomes.
Dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify a patient's true risk of disease progression.
The company is developing prognostic tests,to help healthcare providers identify which patients are most at risk of melanoma disease progression.
it is still too early in the company for this, they are still fundrasing.
1 Sep 2023 to 31 Dec 2024
People are living longer than they did 100 years ago but many spend their later years in poor health. The attention in healthcare is mainly on the prevention of diseases such as skin cancer, by encouraging people to protect their skin from the sun. For older people this can be too late as they will already have signs of skin damage in the form of brown/bl...
1 Oct 2017 to 31 Mar 2018
Melanoma is a skin cancer with an increasing worldwide incidence. The risk of the primary tumour spreading is estimated based on microscopic appearance and depth of the original tumour. Tumours classified as low risk are followed up clinically over five years but approximately 10% of these low-risk (stage I) patients will develop metastatic disease with a...
